Molly Gibson

Molly Gibson is an Origination Partner at Flagship Pioneering, working to found and grow companies at the intersection of AI and science.

At Flagship, Molly co-founded Lila Sciences and Generate: Biomedicines. Today, Molly serves as co-founder and president of Future Science at Lila, a company building the world’s first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. At Generate, she has served many roles from leading early platform build to corporate strategy, platform and data strategy, and launching an innovation group, called G:Labs that explores novel applications of The Generate Platform. Through her role at Flagship Labs, Molly has contributed to the launch and growth of Tessera Therapeutics and Cobalt Biomedicines, which merged into Sana Biotechnology.

Molly received a Ph.D. in computational and systems biology from Washington University in Saint Louis in the Center for Genome Sciences, with the support of a National Science Foundation Graduate Research Fellowship. Molly also holds a B.S. in computer science from Truman State University in Missouri.

While at Washington University, she collaborated with St. Louis Children's Hospital to study the effects of early life interventions on development of the preterm infant gut microbiome and health outcomes. She was also a leader in science outreach and education serving as director and board member of the Young Scientist Program leading over 100 active volunteer scientists with the mission of bringing inquiry-based science to disadvantaged K-12 students. At the graduate level, Molly conceived and developed a bioinformatics course that is now standard for all incoming graduate students in biology and biomedical sciences.

Molly’s work has resulted in multiple pending patents and publications, including articles in Science and Nature. She was honored in 2020 in Endpoints News' 20 under 40 list in biopharma.